Progression‐free survival · children and young adults with diffuse brainstem glioma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · children and young adults with diffuse brainstem glioma
Hyperfractionated radiotherapy showed no clear difference in event‐free survival compared with conventional radiotherapy (low certainty).
1 finding from 1 review
Quality of life · children and young adults with diffuse brainstem glioma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological response · children and young adults with diffuse brainstem glioma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Radiological response defined as the number of participants with a reduction in tumour size > 50% · children and young adults with diffuse brainstem glioma
It is very uncertain whether hyperfractionated radiotherapy changes radiological response defined as the number of participants with a… compared with conventional radiotherapy (very low certainty).
1 finding from 1 review
Toxicities · children and young adults with diffuse brainstem glioma
1 finding from 1 review
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events, reported as "negative experiences" · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
It is very uncertain whether radiotherapy changes adverse events, reported as "negative experiences" compared with botulinum toxin (very low certainty).
1 finding from 1 review
Recurrence · adults with basal cell carcinoma of the skin
Radiotherapy may leads to higher recurrence at 3 years compared with surgical excision (with or without frozen section margin control) (low certainty).
2 findings from 1 review
Cosmetic outcome (good/excellent) · adults with basal cell carcinoma of the skin
Radiotherapy probably leads to lower cosmetic outcome (good/excellent) compared with surgical excision (with or without frozen section margin control) (moderate certainty).
1 finding from 1 review
Pain · adults with basal cell carcinoma of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early treatment failure · adults with basal cell carcinoma of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival
It is very uncertain whether extended‐field chemoradiotherapy changes overall survival compared with pelvic chemoradiotherapy (very low certainty).
1 finding from 1 review
Para‐aortic lymph node recurrence
It is very uncertain whether extended‐field chemoradiotherapy changes para‐aortic lymph node recurrence compared with pelvic chemoradiotherapy (very low certainty).
1 finding from 1 review
Progression‐free survival
It is very uncertain whether extended‐field chemoradiotherapy changes progression‐free survival compared with pelvic chemoradiotherapy (very low certainty).
1 finding from 1 review
Acute adverse events
It is very uncertain whether extended‐field chemoradiotherapy changes acute adverse events compared with pelvic chemoradiotherapy (very low certainty).
1 finding from 1 review
Late adverse events
It is very uncertain whether extended‐field chemoradiotherapy changes late adverse events compared with pelvic chemoradiotherapy (very low certainty).
1 finding from 1 review
Overall survival (5‐year) · women (18 years and older) diagnosed with stage IB2 cervical cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low